• M Ikeda, M Yasui, H Fukunaga, I Seshimo, O Takayama, M Ikenaga, H Yamamoto, M Ohue, M Sekimoto, and M Monden.
• Department of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan. mikeda@surg2.med.osaka-u.ac.jp
• Eur J Cancer Care (Engl). 2005 Dec 1; 14 (5): 435-9.

AbstractThis open label pilot study evaluated the safety and efficacy of the oral 5-HT3 receptor antagonist granisetron for prophylaxis of delayed chemotherapy-induced nausea and vomiting (CINV) in 30 patients with advanced or recurrent colorectal cancer. Patients were studied during two cycles of a 5-week regimen with irinotecan (CPT-11) and UFT. Patients received prophylactic anti-emetic therapy that included intravenous granisetron. If Grade 1 or higher severity gastrointestinal symptoms occurred during 6 days after CPT-11 administration in Cycle 1, then oral granisetron was administered daily for the following 5 days of CPT-11 in Cycle 2. Sixteen patients (53.3%) experienced delayed CINV in Cycle 1. The incidence of Grade 2 or higher vomiting was 32.1% and 27.7% in Cycles 1 and 2 in males (P = 0.554) respectively, and 54.6% and 32.4% in females (P = 0.001) respectively. Granisetron is effective against delayed Grade 2 or higher vomiting induced by CPT-11/UFT in female patients, although granisetron alone may not sufficiently control nausea induced by this regimen.

25 keywords...

hide…